OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Income Before Tax

Last Annual Value

-59.52M

3-Year CAGR

-26%

5-Year CAGR

-25%

10-Year CAGR

-12%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Income Before Tax

OKUR · NASDAQ
CompanyIncome Before Tax
CAGR 3Y
CAGR 5Y
CAGR 10Y
-59.52M
N/AN/AN/A 
-35.67M
N/AN/AN/A
-56.03M
N/AN/AN/A
-23.88M
N/AN/AN/A
-26.92M
N/AN/AN/A
-35.04M
N/AN/AN/A
-38.24M
N/AN/AN/A
-68.77M
N/AN/AN/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47